






MECHANISM-DERIVED INHIBITOR DESIGN




GENERAL BASE MECHANISM FOR ZINC PEPTIDASES




CbzGly^PPhe

$K_i = 90 \text{ nM}$ for carboxypeptidase A




CbzGly^PLeuLeu

$K_i = 9 \text{ nM}$ for thermolysin




CbzGly^βPhe

$K_i = 90$ nM for carboxypeptidase A




CbzGly^βLeuLeu




$K_i = 9$ nM for thermolysin




COMPARISON OF PHOSPHONATE AND PHOSPHONAMIDATE INHIBITORS OF THERMOLYSIN



R = H or CC(C)C[C@@H](COP(=O)([O-])OC(=O)C(C)C)C(=O)O








COMPARISON OF PROPOXICACID AMIDES AND ESTERS
INHIBITORS OF SERINEPROTEIN





▲ Y = O, X = NH

■ Y = CH₂, X = NH




Differences in observed binding affinity are due to differences in:


- Solvation of inhibitors
- Conformational properties of inhibitors
- Active site interactions
 - Direct: H-bonding/van der Waals/dipolar effects
 - Indirect: Lewis basicity of oxyanion/carbonyl




DISSOCIATION OF CHEMOTAXIN A BY Che-Val²-(O)Phe
 Determination of k_{on}



If $k_{on} = 1.8 \times 10^8 M^{-1} sec^{-1}$, $K_1 = 10 \mu M \Rightarrow k_{off} = 1.8 \times 10^{-8} sec^{-1}$
 $t_{1/2}$ for dissociation = 14.6 years





DISSOCIATION OF Che-Val²-(O)Phe




$K_1 = \frac{k_{off}}{k_{on}} = 11 \mu M$


Inhibition of Carboxypeptidase A



Inhibition of Carboxypeptidase A
How far down can it go?



STRUCTURE-DERIVED INHIBITOR DESIGN



Strategies for Enzyme Inhibitor Design

Mechanism-Derived

Information required:
Structure of enzyme substrate
Mechanism of enzymatic transformation

Types of inhibitors:
Transition-state or multisubstrate analogs
Suicide inhibitors

Structure-Derived

Information required:
3-Dimensional structure of protein ligand
3-Dimensional structure of protein binding site

Type of inhibitors:
Mimics of known ligands
De novo inventions

